BACE1 and Alzheimer disease: Intranasal administration of siRNA targeting the β-site amyloid precursor protein cleaving enzyme 1 (BACE1) combined with rapamycin, an approved immunosuppressant, led to a reduction in amyloid-beta deposition and improvement of cognition in a transgenic AD mouse model [231].